echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 2.4 billion oral antidiabetic drugs will be launched in the medical insurance admittance negotiation of "medical fast reading society" and there will be enterprise Reviews

    2.4 billion oral antidiabetic drugs will be launched in the medical insurance admittance negotiation of "medical fast reading society" and there will be enterprise Reviews

    • Last Update: 2019-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [November 11, 2019 / medical information list] new regulations are implemented in major provinces of medical device procurement; Pfizer / Merck bavencio research on maintenance treatment of refractory gastric cancer fails; the first new acne drug with new mechanism in 40 years! FDA accepts the application of clascoterone new drug; leukemia bid farewell to chemotherapy! Imbruvica + rituximab program enters FDA real-time review Daily fresh medicine news, speed reading club and you pay attention to! (click on the title to get the original) November 11 news, the National Health Insurance Bureau will start a new round of medical insurance drug access negotiations this week 128 drugs to be negotiated, including 109 Western medicines and 19 Chinese patent medicines, were determined this time (state health insurance bureau) On November 9, according to the official website of the State Council, Chongqing development and Reform Commission held a press conference and issued the notice on holding the hearing on the price adjustment of medical service items in the reform of medical consumables plus in public medical institutions in Chongqing It is pointed out in the document that the scope of centralized procurement of drugs will be expanded, high-value medical consumables procurement will be started timely, and the prices of virtual high drugs and medical consumables will continue to be reduced (Chongqing development and Reform Commission) Just after 0:00 on November 11, it took only 2 minutes and 25 seconds, and the turnover of tmall pharmaceutical industry platform exceeded 100 million After 19 minutes and 09 seconds, Alibaba's health and medical service industry, including medical beauty, Stomatology, physical examination, vaccine, etc., saw a turnover of more than 100 million yuan, more than half of the time compared with last year (Sina Medical News) On November 11, coda biotherapeutics (coda) announced the completion of the US $15 million a + round financing Coda plans to use this round of financing funds to promote the further development of the company's platform and help it consolidate its leading position in the core treatment field In addition, the company plans to launch its chemical gene therapy platform into clinical practice to treat chronic neuropathic pain and focal epilepsy (arterial network) Recently, Pfizer and Merck said that in a three-stage maintenance treatment study (javelin gastric 100), after a successful round of chemotherapy for patients with gastric cancer who are in advanced stage or unable to undergo surgery, bavencio failed to beat the other two treatment options compared with the best support treatment for continuing chemotherapy or prolonging patients' lives The study found that bavencio did not show a good treatment advantage even in PD-1 / L1 positive patients who had historically shown better efficacy of PD-1 / L1 inhibitors (Sina Medical News) Recently, Abercrombie announced that it has submitted a new drug supplement application to the U.S FDA, which will target the anticancer drug imbruvica (ibrutinib, elutinib) and rituximab (rituximab) for the first-line treatment of chronic lymphoblastic leukemia or small lymphoid lymphoma in younger patients (< 70 years old) (Biovalley) Recently, Cassiopea spa, a pharmaceutical company focused on skin diseases, announced that the FDA of the United States has accepted the application of its clascoterone (1% concentration) cream for the treatment of acne The date of PDUFA is August 27, 2020 It is worth mentioning that this is the first new mechanism drug for acne treatment in recent 40 years Clascoterone (also known as cb-03-01) is a local androgen receptor inhibitor, and the new chemical entity is developing treatments for acne (tentatively named winlevi) and male and female hair loss (tentatively named breezula) (Sina Medical News) Recently, Johnson & Johnson's Janssen Pharmaceutical Company announced that it has submitted two marketing authorization applications (MAA) to the European Drug Administration (EMA) for approval of the research-based Ebola vaccine program to prevent Ebola virus disease caused by the Zaire Ebola virus strain Two Maas have been submitted in parallel to support each vaccine (ad26.zebov, mva-bn-filo) In September, the EMA Committee on human pharmaceutical products awarded these applications accelerated assessment qualifications (Biovalley) Recently, gene Taike published the latest clinical results of gazyva (obinutuzumab) in the treatment of proliferative lupus nephritis The trial reached the primary end point, and between 52 and 76 weeks of treatment, the proportion of patients who achieved complete renal remission in the combination of gazyva and standard care was significantly higher than that in the control group Gazayva also reached a critical secondary efficacy endpoint (yaomingkant) A few days ago, AstraZeneca and fabergin announced the summary efficacy and cardiovascular (CV) safety analysis of roxadustat Losartan is a "first in class" inhibitor of prolyl hydroxylase, a hypoxia inducible factor A pooled CV safety analysis showed that rosaristad did not increase major cardiovascular adverse events and all-cause mortality compared to placebo in patients with non dialysis dependent renal anemia Compared with the current standard therapy, erythropoietin did not improve mace and all-cause mortality in patients with dialysis dependent renal anemia (yaomingkant) On November 9, shengjitang announced that its wholly-owned subsidiary, shengjitang pharmaceutical, had received the approval document for supplementary drug application issued by the State Food and Drug Administration on glimepiride tablets (2mg), which passed the consistency evaluation of quality and efficacy of generic drugs According to the data of minenet, in 2018, among the top 20 generic names of terminal oral diabetes drugs in public medical institutions in China, glimepiride ranked the third with a sales volume of 2.4 billion yuan (meter net) Recently, Zhao Fengguang, Secretary of jiankangyuan, revealed that tobramycin inhalation solution of the company is expected to become the first inhaled antibiotic drug in China The data shows that the clinical application of class 2.4 new drug of tobramycin inhalation solution of jiankangyuan was approved in October 2017, and now it has entered into phase III clinical (meter net)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.